PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award Apr 02, 2020 9:30am EDT
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing Mar 31, 2020 9:30am EDT
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device Mar 09, 2020 9:30am EDT
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients Mar 02, 2020 9:30am EST
PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™ Feb 20, 2020 9:30am EST
PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline Feb 18, 2020 9:30am EST
U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test Feb 11, 2020 9:30am EST
PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test Dec 19, 2019 9:30am EST
